Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- elafibranor
- Enablex (darifenacin)
Interactions between your drugs
darifenacin elafibranor
Applies to: Enablex (darifenacin), elafibranor
MONITOR: Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of darifenacin, which has been shown to be a substrate of the isoenzyme.
MANAGEMENT: Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary.
References (1)
- (2005) "Product Information. Enablex (darifenacin)." Novartis Pharmaceuticals
Drug and food interactions
darifenacin food
Applies to: Enablex (darifenacin)
The consumption of grapefruit juice may be associated with increased plasma concentrations of darifenacin. The mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. The clinical significance is unknown.
References (1)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Ocaliva
Ocaliva may be used to treat primary biliary cholangitis (PBC) in adults without cirrhosis or with ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Livdelzi
Livdelzi (seladelpar) is an oral prescription medicine that may be used to treat primary biliary ...
Actigall
Actigall is used for gallbladder disease, primary biliary cholangitis
Iqirvo
Iqirvo (elafibranor) is used to treat primary biliary cholangitis (PBC) in combination with ...
Urso Forte
Urso Forte is used for gallbladder disease, primary biliary cholangitis
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.